Celsion to Hold Annual Meeting

Shareholders May participate by Telephone or Webcast

Jun 22, 2010, 07:30 ET from Celsion Corporation

COLUMBIA, Md., June 22 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company that is leveraging its heat sensitive liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, will hold its Annual Meeting of Shareholders on Friday, June 25, 2010 at 10:00 a.m. ET at Hyatt Regency Baltimore, 300 Light Street, Baltimore, MD 21202.

Shareholders who are unable to attend the meeting are invited to participate by telephone or audio webcast.  Please contact Marcy Nanus at 646-378-2927 or mnanus@troutgroup.com for dial-in information or the webcast registration code.  The webcast can be accessed on the Company's website at www.celsion.com

About Celsion

Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems.  Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers.  Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong King, Cleveland Clinic, and the North Shore Long island Jewish Health System.

For more information on Celsion, visit our website:  http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the 'safe harbor" provisions of the Private Securities Litigation Reform, Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

CONTACTS:

Marcy Nanus

The Trout Group

646-378-2927

mnanus@troutgroup.com

Lily Ifield

Celsion Corporation

410-290-5390

SOURCE Celsion Corporation



RELATED LINKS

http://www.celsion.com